Explore

ASCO Highlights Challenges in Cancer Care Due to War, Disasters, and Policy

ASCO Highlights Challenges in Cancer Care Due to War, Disasters, and Policy

At the ASCO 2026 education session, experts discussed the compounded challenges in cancer care arising from war, natural disasters, and policy decisions. The session highlighted the plight of displaced Africans, survivors of climate-related disasters, and undocumented immigrants in the U.S. Dr. Nazik Hammad emphasized the lack of cancer care infrastructure in conflict zones, while Dr. Manali Patel pointed out the disruption of medical services due to natural disasters. Dr. Patricia Mae Garia Santos addressed the limited access to cancer care for undocumented immigrants, exacerbated by policy restrictions under the Affordable Care Act. These discussions underscored the need for global solidarity and policy advocacy to ensure equitable cancer care access.

GRAIL's Galleri Test Enhances Early Cancer Detection at ASCO Meeting

GRAIL's Galleri Test Enhances Early Cancer Detection at ASCO Meeting

GRAIL, Inc. has presented the results of its PATHFINDER 2 study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study involved 35,878 participants and evaluated the Galleri multi-cancer early detection (MCED) test. The test screens for over 50 types of cancer, including those without current screening options, such as pancreatic and ovarian cancers. The Galleri test demonstrated a 6.5-fold increase in cancer detection when added to standard screenings for breast, colorectal, cervical, and lung cancers. Notably, 71% of the new cancers detected were in stages I-III, allowing for potentially curative treatments. The test also showed a low false positive rate and high accuracy in predicting the cancer signal origin, facilitating efficient diagnostic evaluations.

Lifestyle Changes Post-Cancer Diagnosis May Improve Survival Rates

Lifestyle Changes Post-Cancer Diagnosis May Improve Survival Rates

Lifestyle Changes Post-Cancer Diagnosis May Improve Survival Rates

Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection Trials

Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection Trials

Grail, a Silicon Valley healthcare company, has presented its largest study to date on the Galleri blood test at the American Society of Clinical Oncology meeting in Chicago. The test, priced at $950, aims to detect over 50 types of cancer by identifying cancer DNA in the bloodstream. The study involved more than 140,000 older individuals in the UK, assessing the test's ability to detect cancer before it reaches advanced stages. While the test increased cancer detection rates when combined with standard screenings, it was less effective at identifying early-stage cancers, which are generally easier to treat. The test is not yet FDA-approved but is available in the U.S. with a prescription.

Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection

Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection

Grail, a healthcare company based in Silicon Valley, has developed a $950 blood test called Galleri, designed to detect over 50 types of cancer early. The company presented its largest study at the American Society of Clinical Oncology meeting in Chicago, involving over 140,000 older participants in the UK. The study aimed to determine if the Galleri test could detect cancer before it reached advanced stages. While the test identified additional cancer cases, it missed a significant number, with a sensitivity of around 30%. The test is not yet FDA-approved but is available in the U.S. with a prescription. Despite its limitations, the test showed potential in detecting certain early-stage cancers, such as ovarian and esophageal cancers.

Study Links Moderate Coffee and Tea Consumption to Lower Dementia Risk in U.S. Adults

Study Links Moderate Coffee and Tea Consumption to Lower Dementia Risk in U.S. Adults

Study Links Moderate Coffee and Tea Consumption to Lower Dementia Risk in U.S. Adults

GRAIL's Galleri Test Shows Significant Increase in Cancer Detection at ASCO Meeting

GRAIL's Galleri Test Shows Significant Increase in Cancer Detection at ASCO Meeting

GRAIL, Inc. presented the results of its PATHFINDER 2 study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the effectiveness of the Galleri Multi-Cancer Early Detection (MCED) test. The study involved 35,878 participants aged 50 and older, with no clinical suspicion of cancer, across the U.S. and Canada. The Galleri test, when added to standard cancer screenings, increased cancer detection by 6.5 times. Notably, 71% of the new cancers detected were in stages I-III, where treatment is more likely to be successful. The test demonstrated a positive predictive value of 60.3% and a specificity of 99.6%, indicating a low false-positive rate. The Galleri test also accurately identified the cancer signal origin 91.3% of the time, facilitating efficient diagnostic workups.

U.S. Healthcare System Criticized for High Costs and Poor Outcomes in Global Report

U.S. Healthcare System Criticized for High Costs and Poor Outcomes in Global Report

The Commonwealth Fund's 2026 report card on U.S. healthcare highlights significant shortcomings compared to other wealthy nations. Despite spending 18% of its economy on healthcare, the U.S. achieves poor results, with life expectancy below peers and high rates of preventable deaths. The report grades coverage, affordability, delivery of care, and equity, with the U.S. failing or nearly failing in each area. The country lacks guaranteed coverage for all, with 27 million uninsured Americans. The report also criticizes the U.S. for having the fewest primary care doctors per capita and high maternal mortality rates among Black women. Internationally, the U.S. has reduced its role in global health aid, leading to projected increases in preventable deaths worldwide.

Research Links Poor Sleep to Increased Cancer Risk in Under-50s

Research Links Poor Sleep to Increased Cancer Risk in Under-50s

Recent studies presented at the American Society of Clinical Oncology's annual meeting in Chicago have highlighted a potential link between poor sleep patterns and an increased risk of early-onset cancers in individuals under 50. Conducted by the MD Anderson Cancer Center in Houston, the research analyzed health data from over 18 million U.S. adults aged 18 to 50. Findings suggest that those with irregular sleeping patterns are more likely to develop cancers such as bowel, breast, uterine, or ovarian cancer. In some cases, individuals diagnosed with insomnia were found to be three times more likely to develop cancer within five years. The studies underscore sleep disruption as a potentially modifiable risk factor in early-onset cancer risk stratification, warranting further investigation.

Kelun-Biotech Presents Phase II Data for Lunbotinib Fumarate in RET Fusion-Positive NSCLC at ASCO

Kelun-Biotech Presents Phase II Data for Lunbotinib Fumarate in RET Fusion-Positive NSCLC at ASCO

Kelun-Biotech Presents Phase II Data for Lunbotinib Fumarate in RET Fusion-Positive NSCLC at ASCO

US adult cigarette smoking rate hits another all-time low

US adult cigarette smoking rate hits another all-time low

The cigarette smoking rate among U.S. adults dropped to another all-time low last year

ASCO 2026 to Highlight Global Shift in Oncology Innovation with Increased Chinese Influence

ASCO 2026 to Highlight Global Shift in Oncology Innovation with Increased Chinese Influence

The upcoming ASCO 2026 conference is set to showcase significant shifts in oncology innovation, with a notable increase in contributions from China. Analysts have observed that nearly one-third of presentations at last year's ASCO involved assets originating in China, highlighting a trend towards more globally distributed innovation. This shift is reshaping traditional assumptions in the pharmaceutical industry, as companies align research and development, communications, and commercial strategies earlier than before. The conference will explore how innovation, regulation, and commercialization are becoming interconnected across global markets, with China emerging as a key player in drug development and approval processes.